Poor prognosis of most cancer patients is in part, due to limited therapeutic options. Furthermore, as chemotherapy remains the standard-of-care for several cancers, partial or lack of response remains a concern and compounding this are the adverse side effects of the treatment that severely impacts the quality of life and survival. In pursuit of improving treatment options, we have opted to investigate the unique chemical skeleton of natural compounds as anticancer therapies. In this study, from an initial screen of 31 crude methanol extracts from ~15 plant species using HL60 cells, the root extract of Brucea javanica (L.) Merr indicated the presence of bioactive compounds. Subsequent bioassay-guided purification on the root extract yielded two alkaloids canthin-6-one (1) and bruceolline J (2), which were further investigated for their bioactivity in representative human cancer lines and normal phenotypic counterparts. MTT assay demonstrated ED 50 values from 34.7-72.9 µM for 1 and 16.0-54.0 µM for 2 for the cancer cell lines panel. NP69 cells also demonstrated sensitivity to both compounds (9.3 µM and 4.5 µM). As amount of 2 isolated were limiting, we focused on 1 to further identify novel anticancer properties in PC3 and HeLa cancer lines. We observed at 30 µM, 1 induced a G 2 /M phase arrest coinciding with decreased cell proliferation. Furthermore, 1 was able to synergize the cytotoxic effect of cisplatin when used in combination, suggesting the potential of combination therapy for those less responsive lesions to standard chemotherapy.
With ~8.2 million cancer deaths reported for 2012, 60% were from the Asian sub-population [1] , including Malaysia, where this disease currently represents the third leading cause of death, with nasopharynx, prostate, breast, and colorectal cancers being reported as among the most frequently diagnosed [2] . As treatment options go, cytotoxic agents, including platinum-based drug, taxanes and camptothecin analogs, remain the standard-of-care for several cancers (breast cancer, ovarian cancer, non-small cell lung cancer, and bladder cancers) [3] [4] [5] . However, key limitations with this class of cancer therapy are primarily their non-specificity on healthy dividing cells, acquired resistance [6] , and side-effects, including mucositis [7] .
There is a growing body of evidence indicating anticancer therapies derived from natural products induce cell cycle blockade. Examples include trabectedin (Yondelis ® ) and flavopiridol; which cause cells to accumulate in the G 2 /M phase of the cell cycle [8, 9] . This effect can be exploited for sensitizing cancer cells to existing therapies that alone are either extremely toxic or with minimal effect. For instance, when flavopiridol was used in combination with irinotecan in patients with advanced solid tumors, 36% of the patients were with prolonged stable disease (≥12 months) without cumulative toxicity [10] . This study reiterates a need for the continuous discovery of new anticancer drugs with the view of modifying existing treatment regime to improve patient outcomes.
Natural products represent a robust resource of diverse chemical scaffolds for drug development [11] . To this end, over 50% of all small molecules based approved drugs have originated from natural sources [12] . Noteworthy, Principal Component Analysis (PCA) of naturally isolated secondary metabolites and FDA-approved anticancer therapies showed close similarities suggesting the potential of developing the next anticancer drug from natural resources [13] . Notwithstanding, ~15% of all higher plant species have been systematically investigated [14] leaving a vast untapped valuable resource including uncultivable marine microbes for discovering novel drug entities [14, 15] . As one of the mega biodiverse countries in the world [16] , Malaysian natural resources can likely contribute to this effort.
Brucea javanica (L.) Merr, commonly known as lada pahit in Malaysia, is a shrub from the Simaroubaceae family and is widely distributed from Southeast Asia to Northern Australia [17] [18] [19] [20] . A large number of studies on this plant have primarily focused on the fruit and seeds, which are commonly used in ethnomedicinal practices for the treatment of lung and gastrointestinal cancers (China) [21] , anti-bacterial and anti-fungal infections (Indonesia) [22] , anti-diarrheal (Thailand) [23] , treatment of malaria and dysentery (Cambodia) [24] , as well as diabetes mellitus (Malaysia) [25] . Furthermore, B. javanica extracts have also been shown to have anti-inflammatory (seeds methanol extract) [26] , antitrypanosomal (fruits ethyl acetate extract) [27] and anti-phytoviral activities (seeds ethanol extract) [28] . Phytochemical studies on various species of Simaroubaceae family have identified quassinoids and alkaloids as the two major types of chemical constituents present [29] . Quassinoids and indole alkaloids have been previously shown to induce cytotoxic effects on various human cancer lines (for example Lu1, LNCaP, MCF7, HL60, HCT116,  HT29, OVCAR3, A498, PC3, PANC1) [20, 30, 31, 32, 33] , and one of the quassinoids, bruceantin was shown to confer cytotoxicity with ED 50 values of between 2 to 12 µM [20] . Furthermore, Tran et al. demonstrated that by using a TNF-α-stimulated HEK293-NF-κB-Luc reporter system, canthin-6-one alkaloids were able to inhibit NF-κB pathway activation at favorable concentrations (3.8-19.5 µM) [34] . With a wide range of bioactivities reported for B. javanica and limited studies on the root, investigation of cancers endemic in Malaysia were explored to look for potential novel (Table A1 , Supplementary data) provided by the Forest Research Institute Malaysia (FRIM), were prepared into 31 crude methanol extracts and evaluated for the presence of bioactivity using human promyelocytic leukemia (HL60) cells primarily due to their suitability for rapid screening [35] . From this initial assessment, B. javanica extracts of different parts (leaves, branches, roots) were bioactive at concentrations of ~20 µg/mL, by giving cell viabilities of 13.7%, 16.3% and 28.2%, respectively, after 48 h of exposure (Table A1 , Supplementary data). All extracts of the remaining plant species broadly displayed higher cell viability (70-100%) suggesting insignificant potency, with the exception of leaf component of Vitex trifolia subsp. litoralis Steenis, which gave a response of 30%. V. trifolia is known to contain diterpenoids and flavonoids [36] , which likely contribute to the cytotoxicity of the extract. Study by Wu et al. showed an isolated diterpenoid exhibited ED 50 values in the range of 4-28 µM in HeLa cells when treated over 72 h [36] . As it was only the crude extracts of the different parts of B. javanica that were demonstrating notable bioactivity, we opted to focus on the root part for our subsequent studies, as it represented the least investigated, thus providing an opportunity to identify novel compounds of interest. With this aim, the root methanol extract was further assessed on a sub-set of human cancer cell lines (PC3, HeLa, MCF7, HCT116) and NP69 (immortalized normal epithelial) cells, used primarily as normal equivalents. From the MTT assays, root methanol crude extract demonstrated that broadly all the cancer (PC3: 9.1 µg/mL; HeLa: 13.2 µg/mL; MCF7: 6.5 µg/mL; HCT116: 5.0 µg/mL) and normal (NP69: 3.4 µg/mL) cells, showed sensitivity, with ED 50 values less than 15 µg/mL ( Figure A1 , Supplementary data). Bioassay-guided isolation were conducted on the root methanol crude extract using chromatography methods routinely used in our laboratory and as previously described against HL60 cells [37] . Briefly, fractionation and purification were performed using the solvent system optimized for chemical profiling of the crude extract using analytical high performance liquid chromatography (HPLC) (Table A2 and Figure A2 , Supplementary data) and this has led to the identification of two known alkaloids, canthin-6-one (1) and bruceolline J (2).
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Identification of both compounds was made by comparison of their spectral data with those in the literature. The chemical structure of 1 was confirmed by NMR spectroscopy, further supported by the HRMS analysis [38, 39] . This study represents the first report of 1 from the root of B. javanica. Most of the previous reports indicated the isolation of 1 from cell suspension cultures of B. javanica [40] . Of note, the Brucea species is well-known for its slow growth rate and thus in vitro plant cell culture systems are the most efficient approach currently available for obtaining sufficient amounts of material for further investigation on this plant species [40] . Similarly, the second isolated alkaloid, bruceolline J, was characterized by NMR spectroscopy and HRMS analysis and the obtained data are comparable with literature [41] . This alkaloid was initially isolated from the stem of Brucea mollis Wall. (Simaroubaceae) [41] and our study here represents the first report identifying 2 from B. javanica root.
As the extract demonstrated bioactivity on a panel of human cancer and normal cell lines, 1 and 2 were then systematically evaluate in parallel with cisplatin as control, using human cancer and normal cells. As seen in Figure 2, . NPC252 cells were not tested with 2 due to low availability of the compound. Broadly, ED 50 results fall in line with those previously reported by Chen et al. [41] , whereby the average ED 50 value for 2 isolated from B. mollis, was greater than 10 µM against colorectal adenocarcinoma (HCT8), hepatocellular carcinoma (BEL7402), gastric cancer (BGC823), lung carcinoma (A549), and ovarian carcinoma (A2780) lines, after a longer (96 h) treatment time. Currently, study by Chen et al. represents the only reported study on the isolation and identification of 2, and with the exception of cytotoxicity no other biological characterization has been undertaken and thus represents an area for further investigation [41] . However, a key challenge encountered in the current study, was the low amounts of 2 isolated due to indole alkaloids not being major constituents of B. javanica, and limiting the subsequent studies [43] . Furthermore, as 2 was not commercially available, the subsequent assay will only focus on 1, which was readily available, for further characterization on two cancer lines (PC3, HeLa) as representative of commonly diagnosed cancers in Malaysia [44] . To date there is only limited information on the impact of 1 on known human cancer hallmarks, specifically on cancer cells ability in sustaining cells proliferation [45] . A recent study by Dejos et al. using PC3 cells found that 1 stopped cell proliferation and induced a robust G 2 /M cell cycle block at concentrations of ~40 µM after 48 h of exposure time. To exploit this effect on the cell cycle, 1 was first assessed on its ability to reproduce the reported observations on PC3 and HeLa cells. The effect of 1 on cell cycle distribution was analyzed by flow cytometry using two different concentrations (30 and 100 μM) as indicated to reflect the average ED 50 values for these two lines and the highest concentration tested in the entire assay for this study. As seen in Figure 3 , when compared to the control groups, both lines treated with 100 µM of 1 showed a significant G 2 /M cell cycle arrest which was accompanied by an increase in the G 2 cell population (64.7%) together with a reduction in the G 1 phase (27.5%) after 48 h of treatment. However, the effect with a lower dose of 1 was observed to be modest for both lines, with average of 19.5% and 6.0% for G 1 and G 2 cell populations, respectively. As 1 was likely interfering with cell division, its ability in inhibiting DNA synthesis was assessed using the Click-iT assay. Essentially in this assay, the nuclei of viable cells are counterstained with blue (DAPI) whereas proliferating cells with active DNA synthesis are labelled red (Alexa) as seen in Figure 4A . The overlap between images of viable cells over actively proliferating cells illustrates the percentage of proliferating cells when compared to total viable cells. Choosing the same concentration (30 µM) that gave a modest response in our cell cycle analysis together with a 48 h exposure time, a reduction in proliferating cells were observed with little indication of cell death in both PC3 and HeLa cells. Broadly, 1 is likely inhibiting DNA synthesis to prevent PC3 and HeLa cells to undergo mitosis as seen in Figure 4A and A3 in Supplementary data. By counting the positively labelled control and treated cells, a reduction of almost 40% was noted ( Figure 4B ). This data are consistent with those reported by Dejos et al. who demonstrated that in the presence of 1, a reduction in DNA replication and proliferating cells by ~60% were observed using similar treatment time (48 h) but with a slightly higher concentration (40 µM). The study also reported that 1 possessed the ability to interfere with mitotic spindle formation, resulting in ~80% decrease when cells were treated with 40 µM of 1 [44] . As the cell cycle data of 1 coincided with those reported by Dejos et al. [46] , the key proteins involved in the observed G 2 /M cell cycle blockade were further determined. For this, only PC3 cells were used as our prior data together with those described by Dejos et al., indicating that 1 was inducing a robust G 2 /M block with 30-40 µM on PC3 cells. Prior to analysis, PC3 cells were treated with aphidicolin with the aim of synchronizing cells in the G 1 phase. Next, cells were released and treated with 30 µM 1 and harvested after 6, 12 and 24 h of incubation. A parallel set of controls were also collected by treating cells with vehicle control (1% DMSO) using similar conditions. All cells were processed for flow cytometry and Western blot analysis. As seen in Figure 5 , control treated (-1) non-synchronized proliferating cells broadly showed a normal cell cycle profile, while those released from a G 1 block traversed to G 2 /M within 6 h prior to cell division and back to the start of the cycle (12-24 h). In the presence of compound (+1), cells are observed to be accumulating in G 2 /M (12 h) prior to entering G 1 but with a notable population still observed in G 2 /M (24 h). Biochemical analysis of the protein lysates was with the premise that a G 2 /M block would phosphorylate cdc2 residues Thr 14 and Tyr 15 for inactivation to prevent mitosis. However, under the experimental conditions used, no significant differences were observed between the two groups, while the steady state levels of total cdc2 were unchanged and tubulin was used as a loading control ( Figure A4 , Supplementary data). Likely explanation may be the less robust G 2 /M blockade achieved with 30 µM for 24 h. Related proteins, including the cyclin dependent kinase inhibitors (CDKI), p21WAF and p27, also showed minimal difference on treatment with 1 (data not shown). [54] , and sensitizes to SN38 (an active metabolite of irinotecan) treatment which was found to be consistent with in vivo data and suggesting a clinical utility of this combination therapy for patients with Ewing sarcoma [57] . Thus, as 1 was inducing a G 2 /M block in this study and as reported [46] , the potential of the compound to synergize with standard of care cytotoxic cancer therapies was analyzed. In this study, PC3 cells were exposed with either cisplatin or irinotecan at a range of concentration for 24 h followed by treatment with 30 µM of 1 for an additional 24 h. From this investigation (Figure 6 ), 1 did broadly synergized with ~1 µM cisplatin (30 µM being the most effective concentration) after 48 h of treatment giving a coefficient of drug interaction (CDI) values of less than one (0.59-0.91). In view of the synergistic properties and the ability to arrest cancer cells in G 2 /M phase of the cell cycle, 1 can be exploited as combination therapy with platinum based drugs. To this end, Demarcq et al. [58] reported that caffeine, a compound abrogating the G 2 cell cycle checkpoint, demonstrated enhancement for cisplatin-induced toxicity. Chinese hamster ovary CHO/UV41 cells were synchronized with aphidicolin overnight and then released before incubation with 0.5 µg/mL cisplatin for 1 h and were then exposed to 5 mM caffeine to cause G 2 arrest. It was found that the apoptosis process was dramatically increased with the addition of caffeine [53, 58, 59] . On the other hand, combination treatment of 1 with irinotecan gave a minimal synergistic response with varying irinotecan concentrations (1-3 µM), indicated with CDI values of more than one (0.92-1.00). A less pronounced synergistic effect was observed with irinotecan compared to cisplatin probably due to cell-cycle mediated resistance as the sequence of drug treatment may also have an effect in chemosensitivity in combination treatment [53] .
In conclusion, canthin-6-one (1) and bruceoline J (2) isolated from B. javanica root, demonstrated bioactivity across a panel of solid tumor cell lines, with ED 50 values ranging from 34.7-72.9 µM for 1 and 16.0-54.0 µM for 2. Also, 1 was able to induce a G 2 /M block in PC3 and HeLa cells at 30 µM, and this observation was consistent with the anti-proliferative effect of the alkaloid as assessed on Click-iT evaluation. Investigation of the cell cycle protein upon 1 treatment revealed no significant changes in the levels of the phosphorylated and inactivated cdc2, suggesting the potential involvement of other cell cycle proteins which are yet to be defined. A pronounced synergistic effect was observed during combination treatment of 1 with cisplatin, in dose dependent manner raising the possibility for its application as a combination agent with cisplatin in chemotherapy.
Experimental
Chemicals and Reagents: All chemicals and solvents used were of molecular biology, HPLC, LCMS, and analytical reagent grade and purchased from Fisher Scientific (Springfield, New Jersey, USA). MilliQ water (Millipore, Billerica, MA, USA) was used for LCMS analysis. Canthin-6-one (1) was purchased from ChemFaces (Wuhan, China). Leucine-enkephalin and sodium formate for mass spectrometer tuning and calibration were purchased from Sigma Aldrich (St. Louis, MO, USA). Caffeine used as internal standard in mass analysis was bought from EuroScience (Strasbourg, France). Canthin-6-one from Brucea javanica root synergizes with cisplatin Cell Lines: Cancer lines (HL60, PC3, MCF7, HCT116) were purchased from ATCC, while HeLa and NP69 cells, were kindly provided by Professors Lim and Tsao (Academia Sinica, Taiwan and University of Hong Kong, respectively). NPC252 was established from tissue biopsies obtained during surgery. Tissue collection was approved by Tung Shin Hospital (Kuala Lumpur, Malaysia) committee board and with written informed consent from patients. All lines except NP69 and NPC252 were cultured in RPMI 1640 medium supplemented with 1% v/v pen-strep and 10% fetal bovine serum (FBS; Gibco, Life Technologies, Rockville, MD, USA). NP69 cells were cultured in defined-KSFM media and NPC252 cells were cultured in DMEM high glucose supplemented with 10% FBS and 100 U/mL of penicillin and streptomycin solution. All cell lines underwent short tandem repeat genotyping and considered authenticated with a match of >80% (CTRAD, NUS, Singapore).
Isolation and Identification of Pure Compounds:
One gram methanolic extract of the root part of B. javanica was fractionated using solid-phase extraction (SPE) to yield four fractions. Briefly, a Sep-Pak RP C18 SPE cartridge Strata ® purchased from Phenomenex (CA, USA) (Adsorbent weight: 500 mg, bed volume: 6 mL) was pre-conditioned with distilled water (dH 2 O) prior to applying the crude extract. The whole extract was loaded and then eluted through the cartridge with the following solvent systems; dH 2 O (100%), dH 2 O:MeOH (80:20), dH 2 O:MeOH (70:30) and MeOH (100%), each at three times bed volume. All four collected fractions were evaporated using a rotary evaporator (Eyela, Rikakikai Co. Ltd., Tokyo, Japan). The dried fractions were dissolved in 100% DMSO (Fisher Chemical, Fair Lawn, MJ, USA) at 100 mg/ mL prior to assessing bioactivity. Fractions eluted separately with 100% MeOH and dH 2 O from the SPE cartridges identified to potentially contain bioactive compounds were further subjected to preparative HPLC for the isolation and purification of 1 and 2, respectively using Shimadzu HPLC system (Shimadzu, Kyoto, Japan) equipped with pump (model LC-10 AT), a photodiode array detector (PDA; Shimadzu model SPD-20AT vp), and a reverse phase (RP) C18, Chromolith® (Merck, Billerica, MA, USA) preparative column (100-25 mm). Isolation was carried out at a constant flow rate of 10 mL/ min, eluting with dH 2 O (A) and acetonitrile (B) with the following gradient: 0-20% B (0-15 min), 20% B (15-25 min), and finally 20-60% B (25-45 min). 1 was collected at 40.3 min from 100% MeOH SPE fraction (2 mg, 0.20% yield) while 2 (1.3 mg, 0.13% yield) was collected at 25.7 min (from 100% dH 2 O SPE fraction). The isolated alkaloids were profiled for their ultra-violet (UV) absorption and molecular weight using Waters Acquity™ ultra performance liquid chromatography (UPLC) with Acquity™ photo diode array (PDA) detector, coupled with Synapt High Definition Mass Spectrometer (HDMS) Quadrupole-orthogonal acceleration Time-of-Flight (oaTOF) equipped with electrospray ionization (ESI) source (Waters Corporation, Milford, MA, USA). The structures of the isolates were elucidated by analysis of nuclear magnetic resonance (NMR) spectrum obtained using Bruker Avance III 600 MHz Fourier transform (FT) spectrometer equipped with CryoProbe (Billerica, MA, USA) at the National University of Malaysia (UKM, Malaysia).
Cell Viability Assay of Plant Extracts and Compounds:
Extracts and compounds were tested on representative human cancer lines (HL60, PC3, HeLa, MCF7, and HCT116) and normal human immortalized epithelial (NP69) cells and human primary fibroblasts (NPC252) using a concentration range of 0.01 to 100 µg/mL or µM, respectively. Briefly, 1.5x10 4 cells were added to each well of a 96-well microtiter plate and incubated with the plant extracts, fractions, or isolated compounds in three replicate wells (n=3) for 48 h at 37 °C in 5% CO 2 and viability determined by the MTT assay [60] . Cell viability was calculated relative to DMSO (1%) treated cells. Cisplatin was used at a range from 1-100 µM.
Cell Cycle Analysis: PC3 and HeLa cells collected after 48 h of treatment with differing concentrations (30 and 100 µM) of 1, were washed with PBS, fixed with 75% ethanol on ice and stored at -20 °C until processed for analysis. Then, fixed cells were washed with cold PBS followed by staining with PI (10 µg/mL) containing RNase (20 µg/mL) in PBS, for 30 min at 37 °C in the dark. Next, the stained cells were subjected to cell cycle analysis using FACSCanto II operated by BD FACS Diva software (BD Biosciences, San Jose, CA, USA). Aggregates were excluded from the analysis using the doublet discrimination module and subsequent gating on the linear red fluorescence areas and width parameters. Cell cycle distribution profile was generated using ModFit version 4 (Verity Software House, Topsham, ME, USA).
Click-iT Assay for Cell Proliferation:
Cell proliferation was evaluated by the incorporation of 5-ethynyl-2'-deoxyuridine (EdU) using the Click-iT EdU Cell Proliferation Assay (Life Technologies, Rockville, MD, USA). Approximately 6x10 4 cells were seeded on coverslips placed in 12-well plates. Cells were then allowed to attach overnight followed by treatment with 1 (30 µM) or vehicle control (1% DMSO) for 48 h and subsequent incubation with 10 µM EdU for 2 h. Then, cells were fixed in 3.7% paraformaldehyde (Sigma Aldrich, St. Louis, MO, USA) and permeabilized using 0.5% Triton X-100 (MP Biomedicals, Solon, OH, USA) in PBS for 20 min. Next, cells underwent EdU conjugation to Alexa Fluor ® azide using the provided Click-iT reaction protocol. Cell nuclei were counter stained with Hoechst 33342 (Life Technologies, Rockville, MD, USA) for 30 min at room temperature and after washing with PBS, the coverslips were mounted on microscope glass slides using Vectashield ™ mounting medium (Vector Laboratories, Burlingame, CA, USA). Cells were then analyzed under fluorescence using an Olympus IX81 live-cell imaging system equipped with XcellencePro imaging software (Olympus, Tokyo, Japan). The numbers of observed foci were quantified by counting the number of blue nuclei (Hoechst 33342) and red EdU incorporated DNA, separately. The percentage of proliferating cells was calculated as the number of red spots over the blue nuclei stained cells.
Cell Cycle and Western Blot Analysis of Synchronized PC3 cells:
The effect of 1 on cell cycle associated proteins was assessed by cell cycle and Western blot. Exponentially growing PC3 cells were first treated overnight with 10 µM aphidicolin, to synchronize cells in the G 1 /S phase of the cell cycle [61] . Cells were then released by removing the aphidicolin-containing media, rinsed thoroughly with PBS and replenished with fresh medium containing 30 µM of 1 and DMSO (1%). Cells were collected after 0, 6, 12, and 24 h treatment and processed for cell cycle analysis and biochemical analysis. For Western blot, cells were washed with cold PBS and then lysed with 1X RIPA lysis buffer (0.15 M NaCl, 1% Triton X-100, 0.5% sodium deoxy cholate (Sigma Aldrich, St. Louis, MO, USA), 0.1% SDS, 50 mM Tris-HCl pH 8.0), containing protease and phosphatase inhibitor cocktail (Thermo Scientific, Hudson, NH, USA) for 15 min on ice. Lysates were collected into micro centrifuge tubes followed by sonication for 20 s on ice and centrifugation at 14,000 rpm for 20 min at 4 ºC prior to transferring supernatants into clean microcentrifuge tubes. Quantification of total cellular proteins was carried out using Pierce BCA Protein Assay following manufacturer's protocol (Thermo Scientific, Hudson, NH, USA). Fifteen µg of total cellular protein for each sample was denatured and resolved using 15% polyacrylamide gels. After resolution, gels were transferred onto immobilon-P polyvinylidene difluoride membrane (PVDF; Merck Millipore, Billerica, MA, USA) prior membranes blocking using 5% skimmed milk in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20) for 1 h at room temperature. After a brief wash in TBST, membranes were next incubated with primary antibodies at 4 °C overnight. Next, membranes were washed three times with TBST (5 min each time) followed by incubation with secondary antibodies conjugated with horseradish peroxidases (Rockland immunochemicals, PA, USA; 1:5000 in 5% skimmed milk) for 1 h at room temperature. After washing in TBST for 5 min three times, immune complex were detected with Pierce ECL Western Blotting substrate (Thermo Scientific, Hudson, NH, USA) and visualized with FluorChem™ HD2 system (ProteinSimple, Santa Clara, CA, USA) equipped with AlphaView-Fluorchem HD2 software. Primary antibodies (monoclonal mouse anti-human cdc2, monoclonal rabbit phosphorylated cdc2 [Tyr 15], polyclonal rabbit phosphorylated cdc2 [Thr 14]) were used at 1:1000 dilution in 1% BSA in TBST. For cell cycle analysis, the collected cells were processed as described above.
Combination Treatment of Cisplatin and Irinotecan with 1:
Cells were seeded at 6x10 3 cells per well using 96-well plates. A concentration range (0.01-100 µM) of cisplatin and irinotecan was applied to each well and after incubation for 24 h, cells were washed with fresh media and then underwent additional treatment with 1 (30 µM) for 24 h prior to analysis. Cell viability was assessed by MTT essentially as described above. The coefficient of drug interaction (CDI) was calculated in order to analyze the effect of drug combination [62] . The CDI was obtained using the formula CDI=AB/(AxB), where AB is the ratio of drug combination group to the control group and A and B are the ratios of the single treatment groups to the control group. CDI values of <1 indicate that the drugs are synergistic, CDI=1 or >1 is indicative of an additive or antagonistic effect, respectively. CDI <0.7 indicates that the drugs are significantly synergistic.
Statistical Analysis: All data collected in this study were obtained from three independent experiments (n=3). GraphPad Prism 5 software was used for the statistical analysis. Student's t-test was used for the evaluation of differences between the mean values. Values of <0.05 were considered statistically significant. All the data were presented as the mean ± standard deviations (SD). 
